



NATIONAL INFLUENZA VACCINE SUMMIT NEWSLETTER

Influenza Activity Spotlights

Tuesday, January 15, 2008

Issue #12

Professional Medical Organizations

Please disseminate widely to all of your members.

1. Providers who anticipate having excess influenza vaccine in stock following the vaccination season can learn how to obtain a refund for the federal excise tax by visiting the CDC website at www.cdc.gov/vaccines/programs/vfc/forms/excise-tax.htm.
2. Acambis, a leading vaccine development company, announced the [preliminary results](#) from their work on a new influenza vaccine. Phase 1 results of the vaccine, which is a recombinant vaccine linked to a hepatitis B core protein, showed the vaccine to be well tolerated and immunogenic. If successful, the vaccine could overcome the need for annual vaccine reformulations and could also be a potential vaccine against pandemics.
3. GlaxoSmithKline (GSK) [announced](#) that it is now accepting orders for its influenza vaccine (Fluarix) for the 2008-2009 influenza vaccination season. To order through the company's direct ordering website, go to www.GSKvaccinesdirect.com.
4. Implementation challenges of extending the influenza vaccination season are described in a [recent article](#) published in *AMNews*. While some physicians may have been reluctant to order more vaccine because of the financial risk, many have become more comfortable realizing that the recent years of unpredictable vaccine supply seems to be over.
5. The dates for the 2008 National Influenza Vaccine Summit are May 12 and 13, 2008. Please hold those dates in your calendar. Due to cost restrictions, the meeting will be held in Atlanta, Georgia.